• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

American College of Cardiology 71st Scientific Sessions: Science Preview, April 3, 2022


At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.

Late-breaking ACC science on Sunday, April 2, begins at a session jointly sponsored by the ACC and the Journal of the American Medical Association, followed by the joint ACC/New England Journal of Medicine session and a second day of featured clinical research.

Look for studies on icosapent ethyl, vupanorsen, and alirocumab for hypercholesterolemia; for landmark research on HFrEF and on a novel FX1a inhibitor for treatment of atrial fibrillation.

Saturday, April 2, 2022 Late Breaking Clincial Trials

Monday, April 4, 2022 Late Breaking Clinical Trials

More News from ACC on Patient Care

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
© 2024 MJH Life Sciences

All rights reserved.